Evidence map›Paper›PMID 39834094›Full record

ReviewClinical and translational medicine2025

Deciphering the pseudouridine nucleobase modification in human diseases: From molecular mechanisms to clinical perspectives.

Shiheng Jia, Xue Yu, Na Deng, Chen Zheng, Mingguang Ju, Fanglin Wang, Yixiao Zhang, Ziming Gao, Yanshu Li, Heng Zhou and 1 more

Abstract readReview
In one paragraph

Review in Clinical and translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shiheng JiaDepartment of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Xue YuDepartment of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Na DengDepartment of Hematology, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
Chen ZhengDepartment of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Mingguang JuDepartment of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Fanglin WangDepartment of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Yixiao ZhangDepartment of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Ziming GaoDepartment of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Yanshu LiDepartment of Cell Biology, Key Laboratory of Cell Biology, National Health Commission of the PRC and Key Laboratory of Medical Cell Biology, Ministry of Education of the PRC, China Medical University, Shenyang, Liaoning, China.
Heng ZhouDepartment of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Kai LiDepartment of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.ORCID 0000-0003-4244-6855

Funding

National Key R&D Plan 2023YFC2413702
6 · The paper itself

Abstract

RNA pseudouridylation, a dynamic and reversible post-transcriptional modification found in diverse RNA species, is crucial for various biological processes, including tRNA homeostasis, tRNA transport, translation initiation regulation, pre-mRNA splicing, enhancement of mRNA translation, and translational fidelity. Disruption of pseudouridylation impairs cellular homeostasis, contributing to pathological alterations. Recent studies have highlighted its regulatory role in human diseases, particularly in tumourigenesis. Cellular stresses trigger RNA pseudouridylation in organisms, suggesting that pseudouridylation-mediated epigenetic reprogramming is essential for maintaining cellular viability and responding to stress. This review examines the regulatory mechanisms and pathological implications of pseudouridylation in human diseases, with a focus on its involvement in tumourigenesis. Additionally, it explores the therapeutic potential of targeting pseudouridylation, presenting novel strategies for disease treatment. HIGHLIGHTS: Methods to detect pseudouridine were introduced from classic mass spectrometry-based methods to newer approaches such as nanopore-based technologies and BID sequencing, each with its advantages and limitations. RNA pseudouridylation is crucial for various biological processes, including tRNA homeostasis, tRNA transport, translation initiation regulation, pre-mRNA splicing, enhancement of mRNA translation, and translational fidelity. Increased pseudouridylation is frequently associated with tumour initiation, progression, and poor prognosis, whereas its reduction is predominantly implicated in non-tumour diseases. A comprehensive understanding of the inducing factors for RNA pseudouridylation will be essential for elucidating its role in diseases. Such insights can provide robust evidence for how pseudouridylation influences disease progression and offer new avenues for therapeutic strategies targeting pseudouridylation dysregulation. The therapeutic potential of RNA pseudouridylation in diseases is enormous, including inhibitors targeting pseudouridine synthases, the application of RNA pseudouridylation in RNA therapeutics, and its role as a biological marker.

Indexed as

PseudouridineHumansNeoplasmsRNA Processing, Post-TranscriptionalPseudouridinecancerdiseasepost‐transcriptional modificationpseudouridylation

Identifiers

PMID39834094
PMCPMC11746961

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.